PT-141 troches are the route for someone who wants bremelanotide without an injection or nasal spray. Rebody currently offers 1 mg and 2 mg mini troches in eight-count packages. Their advantage is a private oral routine without needles or a nasal pump.
Human trials have not established the clinical outcomes of the finished troches.
The strongest bremelanotide evidence belongs to the FDA-approved injection. Keep that evidence visible without borrowing its dose, timing, or expected results.
Current troche options
| Option | Package | Published routine | Current price |
|---|---|---|---|
| 1 mg mini troche | 8 troches | Dissolve in the cheek as needed before anticipated sexual activity | $109 |
| 2 mg mini troche | 8 troches | Dissolve in the cheek as needed before anticipated sexual activity | $119 |
Current directions limit use to one troche in 24 hours and eight doses per month. The prescription label controls strength, placement, timing, dissolve period, storage, and food or drink rules.
What PT-141 is
PT-141 is bremelanotide, a melanocortin receptor agonist. It works through central sexual-response pathways rather than the blood-flow mechanism used by sildenafil and tadalafil.
This makes it relevant when desire or arousal is the issue under review. It is not a universal erection pill, hormone treatment, lubricant, relationship treatment, or orgasm guarantee.
What a troche changes
A mini troche is placed between gum and cheek or where the label directs. It dissolves over time. Some medicine may cross oral tissue, and some may be swallowed.
Exposure depends on the finished base, contact time, saliva, placement, swallowing, and individual physiology. No public pharmacokinetic study establishes how much bremelanotide reaches circulation from Rebody's 1 mg or 2 mg troche.
The label amount cannot be compared directly with the approved 1.75 mg injection.
What is FDA approved
Vyleesi is a 1.75 mg subcutaneous injection approved for acquired, generalized hypoactive sexual desire disorder in premenopausal women when the condition causes marked distress and is not explained by another condition, relationship issue, or medication effect.
The approval does not extend to a troche, to men, or to every kind of low desire. Rebody's compounded troche is not Vyleesi.
What the evidence can support
Two large phase 3 trials studied the approved injection in premenopausal women with acquired, generalized HSDD. Early research also tested intranasal bremelanotide in small studies involving women and men.
Those studies establish that bremelanotide can affect sexual-response measures under defined routes and protocols. They do not establish oral-mucosal absorption, onset, or outcomes for the troche.
The honest troche case is an as-needed, needle-free, non-nasal routine.
1 mg vs 2 mg
The 2 mg troche contains twice the labeled amount and costs $10 more per package. It is not automatically the better choice.
A clinician can consider medical history, blood pressure, other medicines, prior bremelanotide exposure, tolerance, and the reason for treatment. No comparative clinical trial shows that the 2 mg troche produces a better outcome than the 1 mg troche.
Do not combine strengths or add a second troche because the first did not produce an immediate sensation.
Troche vs nasal spray
Choose the troche when nasal use is the barrier. It avoids congestion, priming, leaking, and spray technique.
Choose nasal spray when administration speed matters more than the mouth-contact routine. The spray also has early intranasal human studies, though they did not test Rebody's bottle.
No head-to-head outcome study establishes a clinical winner. Spray wins on speed. Troche wins when the nose is the problem.
Troche vs injection
The troche avoids needles and injection supplies. The approved injection has a defined dose, prescribing label, pivotal trials, and the strongest safety framework.
Different routes create different absorption and exposure. A 1 mg or 2 mg troche is not a lower or higher version of the injection in any simple sense.
The as-needed routine
Use the troche at the prescribed interval before anticipated sexual activity. Place it where directed and let it dissolve for the full stated period. Follow exact food, drink, and oral-care instructions.
Track timing, early swallowing, taste, mouth irritation, nausea, flushing, headache, blood-pressure symptoms, and the sexual-response problem being assessed. Desire and erection firmness should remain separate measures.
Buccal and sublingual are technique terms
A troche can be placed under the tongue or between the gum and cheek when the label allows it. Those locations expose the dose to oral tissue while it dissolves. Swallowing the troche whole changes the route and should not be treated as an equivalent shortcut.
Contact time, saliva, early swallowing, the troche base, meal timing, and individual oral conditions can change delivery. They also make internet onset claims hard to transfer between products. Use the position and dissolve instructions supplied with the prescription. Do not chew the dose or add another because the first one dissolved faster than expected.
The oral route avoids a needle and a nasal pump. It replaces those steps with uninterrupted dissolve time and a need to plan around food and drink. That trade can work well for someone who dislikes nasal dosing, but it is still a technique-dependent route.
How to compare 1 mg and 2 mg
The current strengths are 1 mg and 2 mg. The higher number means more PT-141 in the troche. It does not prove twice the effect, faster onset, or a better experience. Exposure through the oral lining is not established by the label amount alone.
Strength selection belongs with the prescriber because nausea, flushing, headache, blood-pressure effects, other medicines, and prior response matter. A clear record from the lower prescribed strength can be more useful than a quick jump based on one rushed attempt.
The current eight-count packages cost $109 for 1 mg and $119 for 2 mg. The $10 difference buys a higher labeled strength. Compare it with side-effect tolerance and the prescribed plan, not only milligrams per dollar.
Build a useful as-needed record
Record when the troche was placed, when it finished dissolving, when anticipated sexual activity began, and which outcome mattered. Desire, arousal, erection quality, distress, and satisfaction do not move as one score. Name the one you are trying to change.
Also record nausea, flushing, headache, mouth irritation, alcohol, meal timing, and other sexual-health medicines. A poor response after early swallowing or a late heavy meal may raise a different question from a poor response after careful use.
The maximum of one troche in 24 hours and eight doses per month is a limit. It is not an instruction to repeat quickly when the first result is unclear. Review a pattern with the prescriber before changing strength or route.
Safety questions
The approved injection can temporarily raise blood pressure and lower heart rate. It is contraindicated in uncontrolled hypertension or known cardiovascular disease. Nausea is common.
A compounded troche has a different exposure profile, but the molecule's safety questions remain relevant. Review cardiovascular history, medicines, pregnancy, breastfeeding, and persistent skin darkening with the prescriber.
Seek urgent help for chest pain, severe headache, fainting, breathing difficulty, facial or tongue swelling, or another severe reaction.
Price and package value
The 1 mg package costs $109. The 2 mg package costs $119. Each currently contains eight troches for an as-needed monthly plan.
Compare strength, count, maximum use, clinician review, shipping, storage, and refill terms. Search results often show combination troches containing tadalafil, oxytocin, testosterone, or other ingredients. Those are different products and cannot supply evidence or directions for a PT-141-only troche.
See the current PT-141 troche page for live package details.
What to review at the end of eight doses
Eight troches create a natural review point. Count uses completed with the prescribed placement and dissolve routine. Then compare the chosen outcome, onset pattern, nausea, flushing, headache, oral irritation, and any skipped attempt.
The record should also show which strength was used. Do not mix 1 mg and 2 mg experiences into one average. If the lower strength was easy to tolerate but inconsistent, that raises a different question from a higher strength that produced a strong response with unacceptable nausea.
Bring the pattern to the prescriber before changing strength or moving to nasal spray. The best next route depends on both response and the step that failed: oral contact time, meal timing, nasal tolerance, needle avoidance, or side effects from the molecule itself.
Questions people ask
Is a PT-141 troche FDA approved?
No. The FDA-approved bremelanotide product is the Vyleesi injection.
Is the troche swallowed?
It is placed between gum and cheek or where the label directs and left to dissolve. Do not swallow it whole unless instructed.
How long before sexual activity should I use it?
Follow the pharmacy label. Do not copy injection timing or another clinic's troche directions.
Does it work for men?
Male bremelanotide research used an intranasal route. No troche trial establishes an ED or desire outcome in men.
Can I use more than one?
Current directions limit use to one troche in 24 hours and eight doses per month. Follow the prescription.
Bottom line
PT-141 troches are the practical bremelanotide option when both injections and nasal dosing are poor fits. Choose 1 mg or 2 mg through clinician review. Treat efficacy, onset, and dose comparison as open route-specific questions.